We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Grants Genentech Hearing Over Avastin MBC Indication
FDA Grants Genentech Hearing Over Avastin MBC Indication
February 25, 2011
The FDA has granted a hearing to Genentech allowing the company to defend the metastatic breast cancer (MBC) indication for its biologic Avastin.